HucMSC-Exo Promote Mucosal Healing in Experimental Colitis by Accelerating Intestinal Stem Cells and Epithelium Regeneration via Wnt Signaling Pathway
Xiaonan Liang,Chenyang Li,Jia Song,Airu Liu,Chen Wang,Wenxin Wang,Yaxing Kang,Donglei Sun,Jiaming Qian,Xiaolan Zhang
DOI: https://doi.org/10.2147/ijn.s402179
IF: 7.033
2023-05-25
International Journal of Nanomedicine
Abstract:Xiaonan Liang, 1, &ast Chenyang Li, 1, &ast Jia Song, 1 Airu Liu, 1 Chen Wang, 1 Wenxin Wang, 1 Yaxing Kang, 1, 2 Donglei Sun, 1 Jiaming Qian, 1, 3 Xiaolan Zhang 1 1 Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Hebei Clinical Research Center for Digestive Diseases, Shijiazhuang, Hebei, People's Republic of China; 2 Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China; 3 Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaolan Zhang, Department of Gastroenterology, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang, Hebei, 050000, People's Republic of China, Tel +86 0311-66007370, Email Jiaming Qian, Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China, Tel +86 010-69158100, Email Background: Mucosal healing has emerged as a crucial therapeutic goal for inflammatory bowel diseases (IBD). Exosomes (Exo) as a potential acellular candidate for stem cell therapy might be competent to promote mucosal healing, while its mechanism remains unexplored. Methods: Exosomes derived from human umbilical cord mesenchymal stem cells (hucMSCs) were subjected to experimental colitis mice intraperitoneally to estimate the role in mucosal healing and the regeneration of intestinal stem cells (ISCs) and epithelium. The intestinal organoid model of IBD was constructed utilizing tumor necrosis factor (TNF)-α for subsequent function analysis in vitro. Transcriptome sequencing was performed to decipher the underlying mechanism and Wnt-C59, an oral Wnt inhibitor, was used to confirm that further. Finally, the potential specific components of hucMSC‐exo were investigated based on several existing miRNA expression datasets. Results: HucMSC-exo showed striking potential for mucosal healing in colitis mice, characterized by decreased histopathological injuries and neutrophil infiltration as well as improved epithelial integrity. HucMSC-exo up-regulated the expression of leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5), a specific marker for ISCs and accelerated the proliferation of intestinal epithelium. HucMSC-exo endowed intestinal organoids with more excellent capacity to grow and bud under TNF-α stimulation. More than that, the fact that hucMSC-exo activated the canonical Wnt signaling pathway to promote mucosal healing was uncovered by not only RNA-sequencing but also relevant experimental data. Finally, bioinformatics analysis of the existing miRNA expression datasets indicated that several miRNAs abundant in hucMSC-exo involved widely in regeneration or repair related biological processes and Wnt signaling pathway might be one of the most important signal transduction pathways. Conclusion: Our results suggested that hucMSC-exo could facilitate mucosal healing in experimental colitis by accelerating ISCs and intestinal epithelium regeneration via transferring key miRNAs, which was dependent on the activation of Wnt/β-catenin signaling pathway. Keywords: inflammatory bowel disease, mesenchymal stem cells, exosome, mucosal healing, Wnt/β-catenin signaling pathway The inflammatory bowel diseases, typically categorized as ulcerative colitis and Crohn's disease, are chronic non-specific intestinal disorders. 1 Although the lack of a comprehensive understanding of its underlying pathophysiological mechanisms, it is widely accepted that the interplay between genetic susceptibility, environmental factors and microbial dysbiosis, which mediates dysregulated immune responses, results in the relapsing intestinal inflammation and prolonged mucosal damage. 2 Mucosal healing associated with the improved long-term outcomes in IBD has emerged as a crucial therapeutic goal. 3 Given the prominent role of immune anomalism in IBD, the current armamentarium including untargeted therapies, such as 5-aminosalicylate, glucocorticoids and immunomodulators, as well as targeted biologic therapies, such as anti-TNF agents, anti-integrin α4β7 antibody and anti-IL12/23 p40 antibody, even the novel small-molecule Janus kinase inhibitor all aims to regain the immunological homeostasis, but fails to p -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology